Insider Trading March 25, 2026

Talphera CEO Adds Shares via PIPE; Buys $124,999 Stake

Vincent J. Angotti increases direct holdings after private placement as company navigates trial delay and share-price weakness

By Hana Yamamoto TLPH
Talphera CEO Adds Shares via PIPE; Buys $124,999 Stake
TLPH

Talphera Inc. CEO Vincent J. Angotti acquired 213,310 shares at $0.586 per share on March 13, 2026, for a total of $124,999 as part of a previously announced PIPE. The purchase leaves Angotti with 800,705 directly held shares, including 10,000 from the company’s Employee Stock Purchase Plan. The transaction price was roughly 27% below the current market quote of $0.80; Talphera has a market capitalization of $37.35 million and its shares are down 30% year-to-date. Recent company commentary highlighted robust cash reserves and clinical progress, even as a delayed Nephro CRRT study weighed on investor sentiment.

Key Points

  • Talphera CEO Vincent J. Angotti purchased 213,310 shares at $0.586 per share on March 13, 2026, totaling $124,999.
  • The purchase was executed as part of a previously announced PIPE; Angotti now directly owns 800,705 shares, including 10,000 from the Employee Stock Purchase Plan.
  • Talphera’s stock trades at $0.80, giving the company a market capitalization of $37.35 million, with shares down roughly 30% year-to-date amid a delayed Nephro CRRT study.

Summary

Vincent J. Angotti, chief executive officer of Talphera, Inc. (NASDAQ:TLPH), reported purchasing 213,310 shares of common stock on March 13, 2026, at $0.586 per share, for a total outlay of $124,999. The purchase was disclosed in a Form 4 filing with the Securities and Exchange Commission and was executed as part of a previously announced private investment in public equity (PIPE) transaction.


Transaction details and holdings

The reported acquisition adds to Angotti’s stake in the company. After the PIPE transaction, his direct ownership totals 800,705 shares, which includes 10,000 shares obtained through the company’s Employee Stock Purchase Plan. The stated purchase price of $0.586 represents an approximate 27% discount to the current quoted share price of $0.80. Talphera’s market capitalization stands at $37.35 million, while its stock has fallen about 30% on a year-to-date basis.


Context from company disclosures and recent results

The Form 4 filing identifies this purchase as part of the previously announced PIPE. Separately, Talphera reported fourth-quarter results that coincided with a notable drop in its share price following an update that the company would delay completion of its Nephro CRRT study. During the company’s earnings call, management stressed both its strong cash position and ongoing progress across clinical programs.

Company commentary and the filing together frame a mixed signal: management highlights financial stability and forward movement in trials, while the announced study delay appears to have been a material driver of recent investor concern and the stock’s pullback.


Where investors can find more analysis

The company’s financials and deeper analytical coverage are referenced as available through a Pro Research Report on InvestingPro for those seeking more comprehensive due diligence. Investors remain attentive to Talphera’s clinical timelines and any further updates to funding or study progress.


Note on limitations

The information above is drawn from the company’s regulatory filing and its published quarterly disclosures. Where details are limited in those documents, this report reflects the available statements rather than additional interpretation.

Risks

  • Clinical timeline uncertainty - the delay in completing the Nephro CRRT study has already affected investor sentiment and share price, underscoring execution risk in clinical programs (impacts biotech and healthcare sectors).
  • Market valuation sensitivity - the company’s small market capitalization and recent share-price volatility make it more exposed to investor perception shifts in the small-cap biopharma segment.
  • Limited public detail - available public disclosures provide the core facts of the transaction and recent updates, but finer-grained information on trial timing and operational implications remains constrained.

More from Insider Trading

Photronics Director Disposes $390,000 in Stock; Shares Trade Near Yearly High Mar 25, 2026 SentinelOne President Sells $433K in Stock as Company Announces Leadership and Partnership Moves Mar 25, 2026 SentinelOne Interim CFO Sells 32,221 Shares for About $430,794 as Stock Trades Near $13.36 Mar 25, 2026 SentinelOne CEO Sells Nearly $970k in Stock to Satisfy RSU Tax Withholding Mar 25, 2026 SentinelOne Legal Chief Transfers Shares to Cover RSU Taxes as Company Boosts Leadership and Partnerships Mar 25, 2026